These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26406950)
1. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer. Zhang J; Yu XL; Zheng GF; Zhao F Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950 [TBL] [Abstract][Full Text] [Related]
2. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study. Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis. Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548 [TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis. Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis. Li Y; Zhu M; Zhang X; Cheng D; Ma X Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215 [TBL] [Abstract][Full Text] [Related]
7. Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis. Jia W; Yu T; Cao X; An Q; Yang H Medicine (Baltimore); 2016 Oct; 95(43):e5040. PubMed ID: 27787359 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer. Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874 [TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310 [TBL] [Abstract][Full Text] [Related]
10. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757 [TBL] [Abstract][Full Text] [Related]
11. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054 [TBL] [Abstract][Full Text] [Related]
12. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575 [TBL] [Abstract][Full Text] [Related]
13. Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis. Wang H; Xie F; Hu Z; Chen L Genet Mol Res; 2015 Dec; 14(4):17893-903. PubMed ID: 26782435 [TBL] [Abstract][Full Text] [Related]
14. Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis. Duan L; Hu X; Jin Y; Liu R; You Q BMC Cancer; 2016 Apr; 16():276. PubMed ID: 27090386 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis. Zhang Y; Wu J; Huang G; Xu S Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095 [TBL] [Abstract][Full Text] [Related]
16. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Kim YT; Lee SH; Sung SW; Kim JH Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809 [TBL] [Abstract][Full Text] [Related]
18. Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis. Shi SM; Su ZB; Zhao JJ; Yu DJ; Tu JW; Zhu JQ; Zhao JP; Sheng L; Wang SB; Sheng YJ; Chen HJ; Tian JH; Zhang Y; Wang J J Cancer Res Ther; 2016; 12(1):277-82. PubMed ID: 27072251 [TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis. Qi M; Xiong X Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486 [TBL] [Abstract][Full Text] [Related]
20. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Huang T; Chen X; Hong Q; Deng Z; Ma H; Xin Y; Fang Y; Ye H; Wang R; Zhang C; Ye M; Duan S Sci Rep; 2015 Mar; 5():8897. PubMed ID: 25754026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]